Suppression of the Hypothalamic-pituitary-adrenal Axis by Maximum Androgen Blockade in a Patient with Prostate Cancer.
Suppression of the Hypothalamic-pituitary-adrenal Axis by Maximum Androgen Blockade in a Patient with Prostate Cancer.
复制标题
DOI：
10.2169/internalmedicine.55.7359
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Fukumoto S
中科院分区：
文献类型：
--
作者：
Kondo T;Endo I;Ooguro Y;Morimoto K;Kurahashi K;Yoshida S;Kuroda A;Aihara KI;Matsuhisa M;Abe M;Fukumoto S
一名78岁的日本男性在接受最大雄激素阻断（MAB）治疗（包括醋酸氯地孕酮（CMA））治疗前列腺癌期间出现下丘脑-垂体-肾上腺轴抑制。停止MAB治疗后，基础ACTH水平和对CRH的反应均恢复。虽然没有报告表明CMA抑制前列腺癌患者的下丘脑-垂体-肾上腺轴，但CMA已显示在动物中抑制该轴。这些观察结果表明，我们必须监测下丘脑-垂体-肾上腺轴与CMA治疗的患者，特别是在应激条件下。
A 78-year-old Japanese man showed suppression of the hypothalamic-pituitary-adrenal axis during maximum androgen blockade (MAB) therapy including chlormadinone acetate (CMA) for prostate cancer. After stopping the MAB therapy, both the basal ACTH level and the response to CRH recovered. While no reports have indicated that CMA suppresses the hypothalamic-pituitary-adrenal axis in patients with prostate cancer, CMA has been shown to inhibit this axis in animals. These observations suggest that we must monitor the hypothalamic-pituitary-adrenal axis in patients treated with CMA, especially under stressful conditions.